Wang, X.; Chen, G.; Nie, L.; Wu, Z.; Wang, X.; Pan, C.; Chen, X.; Zhao, X.; Zhu, J.; He, Q.;
et al. IL-2K35C-moFA, a Long-Acting Engineered Cytokine with Decreased Interleukin 2 Receptor α Binding, Improved the Cellular Selectivity Profile and Antitumor Efficacy in a Mouse Tumor Model. Cancers 2022, 14, 4742.
https://doi.org/10.3390/cancers14194742
AMA Style
Wang X, Chen G, Nie L, Wu Z, Wang X, Pan C, Chen X, Zhao X, Zhu J, He Q,
et al. IL-2K35C-moFA, a Long-Acting Engineered Cytokine with Decreased Interleukin 2 Receptor α Binding, Improved the Cellular Selectivity Profile and Antitumor Efficacy in a Mouse Tumor Model. Cancers. 2022; 14(19):4742.
https://doi.org/10.3390/cancers14194742
Chicago/Turabian Style
Wang, Xiaoze, Gang Chen, Lei Nie, Zhenhua Wu, Xinzeng Wang, Chenxiao Pan, Xuchen Chen, Xiaobei Zhao, Jie Zhu, Qiaojun He,
and et al. 2022. "IL-2K35C-moFA, a Long-Acting Engineered Cytokine with Decreased Interleukin 2 Receptor α Binding, Improved the Cellular Selectivity Profile and Antitumor Efficacy in a Mouse Tumor Model" Cancers 14, no. 19: 4742.
https://doi.org/10.3390/cancers14194742
APA Style
Wang, X., Chen, G., Nie, L., Wu, Z., Wang, X., Pan, C., Chen, X., Zhao, X., Zhu, J., He, Q., & Wang, H.
(2022). IL-2K35C-moFA, a Long-Acting Engineered Cytokine with Decreased Interleukin 2 Receptor α Binding, Improved the Cellular Selectivity Profile and Antitumor Efficacy in a Mouse Tumor Model. Cancers, 14(19), 4742.
https://doi.org/10.3390/cancers14194742